It names type 2 diabetes, cardiovascular disease, sleep apnea, and fatty liver disease as scenarios that may justify therapy at a BMI of 27 to 29.9, or in some cases lower
Czechia Dual peptide blend with verified analytical composition Assay content: Ipamorelin 10.26 mg and CJC-1295 11.19 mg Endotoxin level below 0.001 EU/mg No detectable heavy metals or microbial contamination High-purity growth hormone research peptide blend For research use only not for human or veterinary use For laboratory research only
The treatment is especially promising for people seeking to shed pounds quickly due to obesity-related health risks tied to high blood pressure, high cholesterol, and diabetes
[DOI] [PMC free article] [PubMed] [Google Scholar] (549).Wei L
Obesity Reviews, 8(Suppl 2), 85-90
Make sure to see your health care provider for a diagnosis